市場調查報告書

全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場:開發平台治療藥,診斷技術,治療方法,各地區 - 成長,趨勢,預測(2018年∼2023年)

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 649745
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場:開發平台治療藥,診斷技術,治療方法,各地區 - 成長,趨勢,預測(2018年∼2023年) Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 114 Pages
簡介

全球非酒精性脂肪性肝炎(NASH)治療藥及診斷市場在2018年到2023這段調查期間中,預測將以25.0%的年複合成長率成長。糖尿病及肥胖症的盛行率上升,研究開發的投資增加等,促進了該市場的成長。就各地區來看,新醫療技術的引進率高,高度優先於研究和開發活動的健全醫療保健基礎設施使得美國興起為最大市場。

本報告提供全球非酒精性脂肪性肝炎(NASH)市場調查,提供市場概要,各技術·用途·各地區的市場趨勢,市場規模的變化與預測,成長要素·阻礙因素以及市場機會·課題分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • NASH療法的利潤管道
    • 全球性糖尿病和肥胖人口的患病率上升
    • 新型生物標誌物技術的出現和肝活檢技術的改進
  • 阻礙因素
    • 缺乏非酒精性脂肪肝病(NAFLD)的有效診斷
    • 治療領域的技術進步停頓
  • 市場機會
  • 主要課題

第7章 非酒精性脂肪性肝炎(NASH)市場:各市場區隔

  • 開發平台治療藥物別
    • 第三階段試驗
      • 二乙酸(OCA)
      • Aramchol(花生酰胺膽鹼酸)
      • Saroglitazar
      • Elafibranor
      • 其他
  • 各診斷技術
    • 成像
    • 肝臟切片檢查
    • 生物標記診斷
    • 其他
  • 各治療法
    • 藥物療法
    • 胰島素抗性改善治療
    • 抗細胞因子治療
    • 外科手術
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭情形

  • 合併·收購分析
  • 協定·聯盟·合作
  • 新產品的上市

第9章 主要企業

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

第10章 市場未來展望

第11章 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 60469

Market Overview

The non-alcoholic steatohepatitis therapeutics and diagnostics market was valued at USD 7932.91 million in 2018 and is expected to reach USD 26776.58 million by 2024, with an anticipated CAGR of 25.89%, during the forecast period (2019-2024). The major factors driving the growth of the market studied are the increase in nash-affected population, the rising global prevalence of diabetic and obese populations, and increasing awareness about NAFLD/NASH. Currently, there are no FDA-approved therapies for NASH. Hence, there is a huge need to find appropriate therapeutic targets for the treatment of NASH. However, the understanding of the pathogenesis and progression of NASH has evolved and several promising novel therapies associated with the same are being evaluated. However, there is no specialized diagnostic test available in the market for NAFLD, and thus, the lack of effective diagnostic tests for non-alcoholic fatty liver disease, the slow advancements in the therapeutics field has been limiting the growth of the market.

Scope of the Report

Non-alcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is the liver inflammation and damage caused by the buildup of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). The products used in the diagnosis and treatment are covered under this report.

Key Market Trends

Selonsertib is Expected to Experience a Lucrative Growth During the Forecast Period

Selonsertib is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic, and anti-fibrotic activities. The major factors driving the growth of the market are the rising prevalence of NASH across the world. The drug targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. It plays a vital role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, and certain types of cancer. In February 2019, one of the market players, Gilead Sciences, announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH), did not achieve its primary endpoint. Thus, in April 2019, it failed the Phase 3 trial, again. However, the drug was generally well tolerated, and safety results were consistent with previous studies. The company is making considerable investments in the development of drugs for NASH. Recently, in April 2019, Gilead Sciences used the AI-based platform of insitro to discover and develop treatments for NASH. Therefore, such type of activities is expected to increase the process of drug development, leading to rapid approval of the drug over the forecast period.

North America Dominates the NASH Therapeutics and Diagnostics Market

The North America market is expected to witness a CAGR of 26.12% during the forecast period. The prevalence of the nonalcoholic fatty liver disease is due to the rising trend of obesity in the region. Nonalcoholic fatty liver disease (steatohepatitis) is considered as the most common form of chronic liver disease. According to a study conducted by the Intermountain Healthcare researchers, on the economic impact of the disease, the nonalcoholic fatty liver disease affects approximately 100 million Americans every year, and the cost of the disease impacting the US healthcare system is nearly USD 32 billion, annually. Another driving factor is the rising number of obese patients in the country. For instance, as per the OECD data, 47% of the adult population in the United States may suffer from obesity by 2030, as compared to 37.7% in 2014. This represents an estimated 25% increase in obesity, by 2030. Therefore, with an increasing number of patients, the diagnostics and therapeutics are also expected to rise in the future in North America.

Competitive Landscape

Several major players, such as Galmed, Intercept, Genfit, Conatus, MediciNova, and Shire, among others, have their NASH drugs in the last stage of clinical trials. The ongoing scientific developments in the pathogenesis of NASH and the identification of novel agents targeting the disease activities are necessary for the further expansion of capacities to treat NASH and to reduce long-term clinical outcomes, such as cirrhosis, liver failure, and cancer. Investors and analysts are still somewhat skeptical about the approval chances of many of the most advanced NASH candidates. Apart from demonstrating the safety and efficacy of NASH treatments, the companies are also dealing with pricing decisions. The NASH pipeline is, therefore, worth keeping an eye on, owing to the rising prevalence of the disease, lack of available proper treatments, and the developing treatment landscape.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in NASH-affected Population
    • 4.2.2 Rising Global Prevalence of Diabetic and Obese Populations
    • 4.2.3 Increasing Awareness about NAFLD/NASH
  • 4.3 Market Restraints
    • 4.3.1 Lack of Effective Diagnostics for Non-alcoholic Fatty Liver Disease (NAFLD)
    • 4.3.2 Slow Advancements in the Therapeutic Field
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Therapeutics
      • 5.1.1.1 Elafibranor
      • 5.1.1.2 Ocaliva
      • 5.1.1.3 Selonsertib
      • 5.1.1.4 Cenicriviroc
      • 5.1.1.5 Emricasan
      • 5.1.1.6 Other Therapeutics
    • 5.1.2 Diagnostics
      • 5.1.2.1 Imaging Techniques
      • 5.1.2.2 Diagnostic Tests
      • 5.1.2.3 Biopsy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 US
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 UK
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Novartis AG
    • 6.1.3 Madrigal Pharmaceuticals
    • 6.1.4 Galmed Pharmaceuticals
    • 6.1.5 Intercept Pharmaceuticals Inc.
    • 6.1.6 Gilead Sciences Inc.
    • 6.1.7 Genfit SA
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Zydus Cadila
    • 6.1.10 Merck & Co.
    • 6.1.11 Viking Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS